Skip to main content
Clinical Trials/NCT03967158
NCT03967158
Active, not recruiting
Not Applicable

Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY

Seung-Jung Park10 sites in 1 country2,000 target enrollmentDecember 23, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Artery Disease
Sponsor
Seung-Jung Park
Enrollment
2000
Locations
10
Primary Endpoint
Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR)
Status
Active, not recruiting
Last Updated
4 months ago

Overview

Brief Summary

The objective of this study is to evaluate effectiveness and safety of Xience Sierra stent in the "real world" daily practice as compared with other drug-eluting stents.

Registry
clinicaltrials.gov
Start Date
December 23, 2019
End Date
December 31, 2028
Last Updated
4 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Seung-Jung Park
Responsible Party
Sponsor Investigator
Principal Investigator

Seung-Jung Park

Professor, Division of Interventional Cardiology. Cardiovascular Center, Asan Medical Center. University of Ulsan, College of Medicine

Asan Medical Center

Eligibility Criteria

Inclusion Criteria

  • Age 19 and more
  • Patient with Xience Sierra Everolimus eluting coronary stent
  • Written consent

Exclusion Criteria

  • Intervention with Xience Sierra Everolimus eluting coronary stent and other drug eluting stent at the same time
  • Life-expectancy less than 1 year
  • Cardiac shock

Outcomes

Primary Outcomes

Composite event rate of death, non-fatal myocardial infarction (MI), or Target- Vessel Revascularization (TVR)

Time Frame: 1 year

Secondary Outcomes

  • Target- Lesion Revascularization(5 year)
  • Myocardial Infarction(5 year)
  • Stent thrombosis(5 year)
  • Target- Vessel Revascularization(5 year)
  • Cardiac death(5 year)
  • Composite event rate of cardiac death or myocardial infarction (MI)(5 year)
  • Stroke(5 year)
  • All cause death(5 year)
  • Procedural Success rate(5 year)
  • Composite event rate of death or myocardial infarction (MI)(5 year)

Study Sites (10)

Loading locations...

Similar Trials